LETTER
Stereoselective Synthesis of Novel D5-Androstenoarylpyrazoline Derivatives
1313
(7) (a) Camoutsis, C.; Nicolaropoulos, S.; Catsoulacos, P. J.
Chem. Eng. 1987, 32, 478. (b) Green, B.; Sheu, K. Steroids
1994, 59, 479. (c) Schaub, R. E.; van den Hende, J. H.;
Weiss, M. J. J. Org. Chem. 1965, 30, 2234.
(8) (a) Hoyte, R. M.; Labaree, D. C.; Fede, J.-M.; Harris, C.;
Hochberg, R. B. Steroids 1998, 63, 595. (b) Szájli, ;
Wölfling, J. Monatsh. Chem. 2006, 137, 1431. (c) Labadie,
S. S. J. Org. Chem. 1988, 53, 3284. (d) Holt, D. A.; Levy,
M. A.; Brandt, M.; Metcalf, B. W. Steroids 1986, 48, 213.
(e) Laitonjam, W. S.; Rajkumar, T. S.; Chingakham, B. S.
Steroids 2002, 67, 203.
(9) Amr, A. E.-G. E.; Abdel-Latif, N. A.; Abdalla, M. M.
Bioorg. Med. Chem. 2006, 14, 373.
(10) (a) Magyar, A.; Wölfling, J.; Schneider, G. Monatsh. Chem.
2003, 134, 1387. (b) Magyar, A.; Wölfling, J.; Kubas, M.;
Seijo, J. A. C.; Sevvana, M.; Herbst-Irmer, R.; Forgó, P.;
Schneider, G. Steroids 2004, 69, 301.
In conclusion, we have demonstrated that the stereoselec-
tive synthesis of androstenopyrazolines can be achieved
by the BF3·OEt2-catalyzed intramolecular 1,3-dipolar cy-
clization of D-seco-hydrazones. The efficacy of pyrazo-
line formation was strongly influenced by substituents on
the phenyl moiety and the reaction conditions.
Acknowledgment
The authors thank I. Simon (University of Szeged, Hungary) for the
NMR spectra. Financial support by the Hungarian Scientific
Research Fund (OTKA T 049366) is gratefully acknowledged.
References and Notes
(1) (a) Pezdirc, L. L.; Jovanovski, V.; Bevk, D.; Jakše, R.; Pirc,
S.; Meden, A.; Stanovnik, B.; Svete, J. Tetrahedron 2005,
61, 3977. (b) Jones, R. C. F.; Hollis, S. J.; Iley, J. N.
ARKIVOC 2007, (v), 152. (c) Norman, M. H.; Heathcock,
C. H. J. Org. Chem. 1987, 52, 226. (d) Grashey, R. In 1,3-
Dipolar Cycloaddition Chemistry, Vol. 1; Padwa, A., Ed.;
Wiley: New York, 1984, 734–814.
(2) (a) Shimizu, T.; Hayashi, Y.; Miki, M.; Teramura, K. J. Org.
Chem. 1987, 52, 2277. (b) Le Fevre, G.; Hamelin, J.
Tetrahedron Lett. 1979, 20, 1757. (c) Fouchet, B.; Joucla,
M.; Hamelin, J. Tetrahedron Lett. 1981, 22, 1333. (d) Le
Fevre, G.; Sinbandhit, S.; Hamelin, J. Tetrahedron 1979, 35,
1821.
(3) Kanemasa, S. In 1,3-Dipolar Cycloaddition Chemistry, Vol.
1; Padwa, A., Ed.; Wiley: New York, 1984, 789–797; and
references cited therein.
(4) (a) Kobayashi, S.; Shimizu, H.; Yamashita, Y.; Ishitani, H.;
Kobayashi, J. J. Am. Chem. Soc. 2002, 124, 13678.
(b) Kobayashi, S.; Hirabayashi, R.; Shimizu, H.; Ishitani, H.;
Yamashita, Y. Tetrahedron Lett. 2003, 44, 3351. (c) Suga,
H.; Funyu, A.; Kakehi, A. Org. Lett. 2007, 9, 97.
(d) Yamashita, Y.; Kobayashi, S. J. Am. Chem. Soc. 2004,
126, 11279.
(5) (a) Bishop, J. E.; Flaxman, K. A.; Orlek, B. S.; Sammes, P.
G.; Weller, D. J. J. Chem. Soc., Perkin Trans. 1 1995, 2551.
(b) Sun, B.; Adachi, K.; Noguchi, M. Tetrahedron 1996, 52,
901. (c) Frank, É.; Wölfling, J.; Aukszi, B.; König, V.;
Schneider, T. R.; Schneider, G. Tetrahedron 2002, 58,
6843. (d) König, V.; Schneider, T. R.; Frank, É.; Aukszi, B.;
Schneider, G.; Wölfling, J. Acta Crystallogr., Sect. E: Struct.
Rep. Online 2002, 58, o810.
(6) (a) Hukki, J.; Laitinen, P.; Alberty, J. E. Pharm. Acta Helv.
1968, 43, 704. (b) Jung, J. C.; Watkins, E. B.; Avery, M. A.
Heterocycles 2005, 65, 77. (c) Fahmy, H. H.; El-Eraky, W.
Arch. Pharm. Res. 2001, 24, 171. (d) Ahn, J. H.; Kim, H.-
M.; Jung, S. H.; Kang, S. K.; Kim, K. R.; Rhee, S. D.; Yang,
S.-D.; Cheon, H. G.; Kim, S. S. Bioorg. Med. Chem. Lett.
2004, 14, 4461.
(11) (a) Karabatsos, G. J.; Taller, R. A. J. Am. Chem. Soc. 1963,
85, 3624. (b) Karabatsos, G. J.; Shapiro, B. L.; Vane, F. M.;
Fleming, J. S.; Ratka, J. S. J. Am. Chem. Soc. 1963, 85,
2784. (c) Bellamy, A. J.; Hunter, J. J. Chem. Soc., Perkin
Trans. 1 1976, 456.
(12) Procedure for the Synthesis of 6c
A mixture of 2 (359 mg, 1.00 mmol), 4-methoxyphenyl-
hydrazine hydrochloride (3c, 175 mg, 1.00 mmol) and
NaOAc (200 mg, 2.44 mmol) in MeOH (5 mL) was stirred
for 1 h at r.t. The white precipitate was filtered off and dried
to give pure 4c (407 mg, 85%). Compound 4c was dissolved
in CH2Cl2 (10 mL) and BF3·OEt2 (0.09 mL, 0.3 mmol) was
added dropwise at 0 °C under a nitrogen atmosphere. After
20 min, the reaction was quenched by the addition of 1 M aq
NaHCO3 (20 mL). The organic phase was separated, the
aqueous phase was extracted with CH2Cl2 (3 × 10 mL) and
the combined organic phases were dried over Na2SO4.
Evaporation in vacuo and recrystallization from CH2Cl2–
hexane afforded 453 mg (95%) of 6c as white crystals;
Rf = 0.32 (EtOAc–CH2Cl2, 10:90). 1H NMR (400 MHz,
CDCl3): d = 0.76 (s, 3 H, 18-H3), 1.05 (s, 3 H, 19-H3), 1.16
(m, 2 H), 1.39 (m, 1 H), 1.44 (d, 3 H, J = 6.0 Hz, 21-H3), 1.51
(m, 1 H), 1.58–1.69 (m, 6 H), 1.80–1.91 (m, 4 H), 2.03 (s, 3
H, 3-Ac-H3), 2.45 (m, 2 H), 2.49 (m, 1 H), 2.77 (d, 1 H,
J = 11.2 Hz, 17-H), 3.65 (m, 1 H, 20-H), 3.78 (s, 3 H, 4¢-
OMe), 4.62 (m, 1 H, 3-H), 5.39 (d, 1 H, J = 4.8 Hz, 6-H),
6.85 (d, 2 H, J = 8.8 Hz, 2¢-H, 6¢-H), 7.05 (d, 2 H, J = 8.8 Hz,
3¢-H, 5¢-H). 13C NMR (100 MHz, CDCl3): d = 14. 4 (C-18),
19.3 (C-19), 20.4 (C-21), 20.7 (CH2), 21.4 (3-Ac-CH3), 25.4
(CH2), 27.7 (CH2), 31.5 (C-8), 31.8 (CH2), 36.8 (C-10), 36.9
(CH2), 37.3 (CH2), 38.1 (CH2), 40.0 (C-13), 50.0 (C-9), 55.6
(4¢-OMe), 57.6 (C-14), 61.3 (C-20), 72.2 (C-17), 73.7 (C-3),
114.3 (2 C, C-2¢, C-6¢), 118.3 (2 C, C-3¢, C-5¢), 121.9 (C-6),
139.9 (C-5), 142.3 (C-1¢), 154.7 (C-4¢), 164.3 (C-16), 170.5
(Ac-CO). MS (EI): m/z (relative intensity) = 476 (100) [M+],
461 (18), 187 (30) [C30H40N2O3].
Synlett 2007, No. 8, 1311–1313 © Thieme Stuttgart · New York